SirnaMed Therapeutics logo
SirnaMed Therapeutics logo

SirnaMed Therapeutics

sirnamed.com
sirnamed.com • HQ: Sewickley, United States • Convertible Note 2024 • 51-200 employees • Founded 2023 • Startup
HQ: Sewickley, United States • Convertible Note 2024 • 51-200 employees • Founded 2023 • Startup
Health Care
Oncology Therapeutics
Claim pageClaim
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$1.3M
1 round on record
Latest round
$1.3M
Convertible Note · Jul 2024 · 2 yr ago
Team
51-200
employees, estimated range
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 10, 2024 Raised a round Convertible Note $1.3M · SEC Form D 2023 Founded
Funding rounds
RoundDateAmountInvestorsSource
Convertible Note Jul 2024 $1.3M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity SirnaMed Therapeutics Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Jing-Zhou HouExecutive Officer, DirectorSEC Form D
Song LiExecutive Officer, DirectorSEC Form D
Phong TranExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs Altay Therapeutics, Yemaachi Biotechnology
NEA
backs 858 Therapeutics
GV
backs PLEASE READ THIS AG
SFC Capital
backs RS RS Scientific logo
Atlas Venture
backs PLEASE READ THIS AG
EcoR1 Capital
backs PLEASE READ THIS AG
Similar startupsby what they do, their industry and backers
Persevere TherapeuticsVenture round $1.6M · 8 mo ago • Founded 2025 • 51-200 employees
Persevere Therapeutics novel drug is focused on improving effectiveness of cancer treatments.
Yemaachi Biotechnology
Yemaachi is creating the world's most diverse cancer bio-database to develop the next generation of cancer drugs that are effective in…
Leucid BioVenture round · 19 mo ago • Founded 2014
CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
PLEASE READ THIS AG
Accent is pioneering a new class of small molecule precision cancer therapies that target critical intracellular dependencies that span…
858 TherapeuticsVenture round $25.2M · 2 yr ago • 201-500 employees
ETX-19477 is a selective PARG inhibitor designed to address DNA damage response vulnerabilities and expand precision treatment options for…
RS RS Scientific logo51-200 employees
RS & RS Scientific leads in cutting-edge cancer therapy research, developing innovative therapies for challenging cancer treatments. Their…

Overview

SirnaMed is committed to developing innovative therapies that directly target the cause of cancer development, progression and treatment resistance. We are creating a world where patients suffering from the most stubborn cancers have both safe and effective treatment options.

People

Jing-Zhou Hou
Executive Officer, Director
SEC Form D
Song Li
Executive Officer, Director
SEC Form D
Phong Tran
Executive Officer
SEC Form D
Stanley Marks
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Sewickley United States
HQ
50-200 est. staff

Financials

Total raised
$1.3M
Latest round
Convertible Note
Funding rounds
1
Funding rounds
Round Announced Amount
Convertible Note 2024 $1.3M Details